• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
CP1

CANNPAL ANIMAL THERAPEUTICS LIMITED - Announcements

0.00% ! 17.0¢
Currently unlisted. Proposed listing date: TBA
Add to My Watchlist

CannPal Animal Therapeutics Limited is an Australia-based pet pharmaceutical company. The... CannPal Animal Therapeutics Limited is an Australia-based pet pharmaceutical company. The Company is focused on research, developing and commercializing therapeutics for the companion animal health industry, using the compounds derived from the cannabis plants. It is focused on cats and dogs. Its lead drug candidate is CPAT-01, which targets osteosarcoma pain in dogs. It is also engaged in investigating and researching the ability to use cannabidiol derived from the hemp plant for developing a nutraceutical range of products for use in companion animals, including dogs, cats, birds, horses and other domestic animals, without a prescription. It is also developing pharmaceutical therapeutics for chronic pain and appetite stimulation. It is developing nutraceutical products for skin conditions, joint health and digestive health.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements



Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
Filters [Clear]
  • Price Sensitive: Yes
CP1 Suspension from Official QuotationPRICE SENSITIVE11/03/21 download Created with Sketch. 230.74KB
CP1 Lodgement of Court Orders with ASICPRICE SENSITIVE11/03/21 download Created with Sketch. 199.03KB
CP1 Court Approves Scheme of ArrangementPRICE SENSITIVE10/03/21 download Created with Sketch. 98.04KB
CP1 Half Yearly Report and AccountsPRICE SENSITIVE19/02/21 download Created with Sketch. 699.54KB
CP1 Appendix 4C - quarterlyPRICE SENSITIVE29/01/21 download Created with Sketch. 387.73KB
CP1 AC8: AusCann Leadership Post CannPal AcquisitionPRICE SENSITIVE08/01/21 download Created with Sketch. 127.2KB
CP1 CannPal and AusCann Enter into Scheme of ArrangementPRICE SENSITIVE16/11/20 download Created with Sketch. 690.38KB
CP1 Trading HaltPRICE SENSITIVE13/11/20 download Created with Sketch. 496.85KB
CP1 Cash Flow Report and Market Update 30 Sep 2020PRICE SENSITIVE29/10/20 download Created with Sketch. 323.43KB
CP1 Quarterly Cash Flow Report Market Update 30 Sep 2020PRICE SENSITIVE29/10/20 download Created with Sketch. 136.76KB
CP1 CannPal Commences Product Registration in South AfricaPRICE SENSITIVE12/10/20 download Created with Sketch. 163.16KB
CP1 Preliminary Final ReportPRICE SENSITIVE20/08/20 download Created with Sketch. 62.54KB
CP1 Quarterly Cash Flow Report Market Update 30 June 2020PRICE SENSITIVE30/07/20 download Created with Sketch. 487.7KB
CP1 DermaCann Reduces Atopic Dermatisis Symptoms in DogsPRICE SENSITIVE21/07/20 download Created with Sketch. 306.43KB
CP1 Quarterly Cash Flow Report & Market Update 31 March 2020PRICE SENSITIVE29/04/20 download Created with Sketch. 1.46MB
CP1 FDA Establishes INAD for CPAT-01PRICE SENSITIVE11/03/20 download Created with Sketch. 191.47KB
CP1 Half Yearly Report and AccountsPRICE SENSITIVE26/02/20 download Created with Sketch. 529.37KB
CP1 Quarterly Cash Flow Report & Market Update 31 Dec 2019PRICE SENSITIVE28/01/20 download Created with Sketch. 330.65KB
CP1 CannPal Enters into Exclusive Licencing Agreement with CSIROPRICE SENSITIVE06/01/20 download Created with Sketch. 436.03KB
CP1 4C Quarterly Cash Flow Report & Market Update Sept 2019PRICE SENSITIVE30/10/19 download Created with Sketch. 405.95KB
CP1 Preliminary Final ReportPRICE SENSITIVE30/08/19 download Created with Sketch. 53.45KB
CP1 Annual Report to Shareholders 30 June 2019PRICE SENSITIVE30/08/19 download Created with Sketch. 6.32MB
CP1 Quarterly Report 30 June 2019PRICE SENSITIVE31/07/19 download Created with Sketch. 640.66KB
CP1 CannPal CPAT-01 Results Presentation and Research AbstractPRICE SENSITIVE06/05/19 download Created with Sketch. 720.41KB
CP1 Quarterly Report 31 March 2019PRICE SENSITIVE24/04/19 download Created with Sketch. 380.13KB
CP1 Half Yearly Report and AccountsPRICE SENSITIVE25/02/19 download Created with Sketch. 912.21KB
CP1 CannPal Receives 2 Key Ethics Approvals to Progress R&DPRICE SENSITIVE13/02/19 download Created with Sketch. 249.63KB
CP1 Quarterly Cash Flow Report & Market Update December 2018PRICE SENSITIVE29/01/19 download Created with Sketch. 419.54KB
CP1 CannPal Completes Phase 1B Cannabinoid Study in DogsPRICE SENSITIVE12/12/18 download Created with Sketch. 258.16KB
CP1 Appendix 4C - quarterlyPRICE SENSITIVE22/10/18 download Created with Sketch. 354.22KB
CP1 CannPal Commences Phase 1B Pharmacokinetic & Safety StudyPRICE SENSITIVE03/09/18 download Created with Sketch. 90.36KB
CP1 Preliminary Final Report 30 June 2018PRICE SENSITIVE31/08/18 download Created with Sketch. 54.23KB
CP1 CannPal enters into MOU with The University of MelbournePRICE SENSITIVE08/08/18 download Created with Sketch. 84.17KB
CP1 CannPal Receives Ethics Approval for Phase 1B Dog StudyPRICE SENSITIVE02/08/18 download Created with Sketch. 85.51KB
CP1 Appendix 4C - Quarterly 30 June 2018PRICE SENSITIVE17/07/18 download Created with Sketch. 139.33KB
CP1 CannPal Enters into Research Agreement with EurofinsPRICE SENSITIVE04/07/18 download Created with Sketch. 86.87KB
CP1 CannPal Research Collaboration with CSIROPRICE SENSITIVE28/06/18 download Created with Sketch. 195.88KB
CP1 Market Update on StudiesPRICE SENSITIVE18/06/18 download Created with Sketch. 89.88KB
CP1 CannPal Enters into Manufacturing Agreement with JayChemPRICE SENSITIVE29/05/18 download Created with Sketch. 88.63KB
CP1 Appendix 4C - Quarterly 31 March 2018PRICE SENSITIVE23/04/18 download Created with Sketch. 135.32KB
CP1 CannPal Imports Cannabis Oils for Clinical TrialPRICE SENSITIVE27/03/18 download Created with Sketch. 85.87KB
CP1 Half Yearly Report and Accounts 31 December 2017PRICE SENSITIVE20/02/18 download Created with Sketch. 1.52MB
CP1 Appendix 4C - Quarterly Cash Flow ReportPRICE SENSITIVE31/01/18 download Created with Sketch. 359.07KB
CP1 CannPal Granted SME Status by the European Medicines AgencyPRICE SENSITIVE18/12/17 download Created with Sketch. 78.7KB
CP1 CannPal Receives Import Consent from APVMAPRICE SENSITIVE07/12/17 download Created with Sketch. 473.05KB
CP1 CannPal Granted Licence to Import from the ODCPRICE SENSITIVE22/11/17 download Created with Sketch. 84.83KB
CP1 CannPal Authorisation to Possess & Supply Medical CannabisPRICE SENSITIVE01/11/17 download Created with Sketch. 85.31KB
CP1 Appendix 4C - Quarterly 30 September 2017PRICE SENSITIVE31/10/17 download Created with Sketch. 186.66KB
CP1 CannPal enters Research Agreement with Queensland UniversityPRICE SENSITIVE30/10/17 download Created with Sketch. 338.68KB
CP1 CP1 Ethics ApprovalPRICE SENSITIVE25/10/17 download Created with Sketch. 86.22KB
CP1 Admission to Official QuotationPRICE SENSITIVE23/10/17 download Created with Sketch. 90.48KB
CP1 Suspension from Official Quotation
11/03/21PRICE SENSITIVE download Created with Sketch. 230.74KB
CP1 Lodgement of Court Orders with ASIC
11/03/21PRICE SENSITIVE download Created with Sketch. 199.03KB
CP1 Court Approves Scheme of Arrangement
10/03/21PRICE SENSITIVE download Created with Sketch. 98.04KB
CP1 Half Yearly Report and Accounts
19/02/21PRICE SENSITIVE download Created with Sketch. 699.54KB
CP1 Appendix 4C - quarterly
29/01/21PRICE SENSITIVE download Created with Sketch. 387.73KB
CP1 AC8: AusCann Leadership Post CannPal Acquisition
08/01/21PRICE SENSITIVE download Created with Sketch. 127.2KB
CP1 CannPal and AusCann Enter into Scheme of Arrangement
16/11/20PRICE SENSITIVE download Created with Sketch. 690.38KB
CP1 Trading Halt
13/11/20PRICE SENSITIVE download Created with Sketch. 496.85KB
CP1 Cash Flow Report and Market Update 30 Sep 2020
29/10/20PRICE SENSITIVE download Created with Sketch. 323.43KB
CP1 Quarterly Cash Flow Report Market Update 30 Sep 2020
29/10/20PRICE SENSITIVE download Created with Sketch. 136.76KB
CP1 CannPal Commences Product Registration in South Africa
12/10/20PRICE SENSITIVE download Created with Sketch. 163.16KB
CP1 Preliminary Final Report
20/08/20PRICE SENSITIVE download Created with Sketch. 62.54KB
CP1 Quarterly Cash Flow Report Market Update 30 June 2020
30/07/20PRICE SENSITIVE download Created with Sketch. 487.7KB
CP1 DermaCann Reduces Atopic Dermatisis Symptoms in Dogs
21/07/20PRICE SENSITIVE download Created with Sketch. 306.43KB
CP1 Quarterly Cash Flow Report & Market Update 31 March 2020
29/04/20PRICE SENSITIVE download Created with Sketch. 1.46MB
CP1 FDA Establishes INAD for CPAT-01
11/03/20PRICE SENSITIVE download Created with Sketch. 191.47KB
CP1 Half Yearly Report and Accounts
26/02/20PRICE SENSITIVE download Created with Sketch. 529.37KB
CP1 Quarterly Cash Flow Report & Market Update 31 Dec 2019
28/01/20PRICE SENSITIVE download Created with Sketch. 330.65KB
CP1 CannPal Enters into Exclusive Licencing Agreement with CSIRO
06/01/20PRICE SENSITIVE download Created with Sketch. 436.03KB
CP1 4C Quarterly Cash Flow Report & Market Update Sept 2019
30/10/19PRICE SENSITIVE download Created with Sketch. 405.95KB
CP1 Preliminary Final Report
30/08/19PRICE SENSITIVE download Created with Sketch. 53.45KB
CP1 Annual Report to Shareholders 30 June 2019
30/08/19PRICE SENSITIVE download Created with Sketch. 6.32MB
CP1 Quarterly Report 30 June 2019
31/07/19PRICE SENSITIVE download Created with Sketch. 640.66KB
CP1 CannPal CPAT-01 Results Presentation and Research Abstract
06/05/19PRICE SENSITIVE download Created with Sketch. 720.41KB
CP1 Quarterly Report 31 March 2019
24/04/19PRICE SENSITIVE download Created with Sketch. 380.13KB
CP1 Half Yearly Report and Accounts
25/02/19PRICE SENSITIVE download Created with Sketch. 912.21KB
CP1 CannPal Receives 2 Key Ethics Approvals to Progress R&D
13/02/19PRICE SENSITIVE download Created with Sketch. 249.63KB
CP1 Quarterly Cash Flow Report & Market Update December 2018
29/01/19PRICE SENSITIVE download Created with Sketch. 419.54KB
CP1 CannPal Completes Phase 1B Cannabinoid Study in Dogs
12/12/18PRICE SENSITIVE download Created with Sketch. 258.16KB
CP1 Appendix 4C - quarterly
22/10/18PRICE SENSITIVE download Created with Sketch. 354.22KB
CP1 CannPal Commences Phase 1B Pharmacokinetic & Safety Study
03/09/18PRICE SENSITIVE download Created with Sketch. 90.36KB
CP1 Preliminary Final Report 30 June 2018
31/08/18PRICE SENSITIVE download Created with Sketch. 54.23KB
CP1 CannPal enters into MOU with The University of Melbourne
08/08/18PRICE SENSITIVE download Created with Sketch. 84.17KB
CP1 CannPal Receives Ethics Approval for Phase 1B Dog Study
02/08/18PRICE SENSITIVE download Created with Sketch. 85.51KB
CP1 Appendix 4C - Quarterly 30 June 2018
17/07/18PRICE SENSITIVE download Created with Sketch. 139.33KB
CP1 CannPal Enters into Research Agreement with Eurofins
04/07/18PRICE SENSITIVE download Created with Sketch. 86.87KB
CP1 CannPal Research Collaboration with CSIRO
28/06/18PRICE SENSITIVE download Created with Sketch. 195.88KB
CP1 Market Update on Studies
18/06/18PRICE SENSITIVE download Created with Sketch. 89.88KB
CP1 CannPal Enters into Manufacturing Agreement with JayChem
29/05/18PRICE SENSITIVE download Created with Sketch. 88.63KB
CP1 Appendix 4C - Quarterly 31 March 2018
23/04/18PRICE SENSITIVE download Created with Sketch. 135.32KB
CP1 CannPal Imports Cannabis Oils for Clinical Trial
27/03/18PRICE SENSITIVE download Created with Sketch. 85.87KB
CP1 Half Yearly Report and Accounts 31 December 2017
20/02/18PRICE SENSITIVE download Created with Sketch. 1.52MB
CP1 Appendix 4C - Quarterly Cash Flow Report
31/01/18PRICE SENSITIVE download Created with Sketch. 359.07KB
CP1 CannPal Granted SME Status by the European Medicines Agency
18/12/17PRICE SENSITIVE download Created with Sketch. 78.7KB
CP1 CannPal Receives Import Consent from APVMA
07/12/17PRICE SENSITIVE download Created with Sketch. 473.05KB
CP1 CannPal Granted Licence to Import from the ODC
22/11/17PRICE SENSITIVE download Created with Sketch. 84.83KB
CP1 CannPal Authorisation to Possess & Supply Medical Cannabis
01/11/17PRICE SENSITIVE download Created with Sketch. 85.31KB
CP1 Appendix 4C - Quarterly 30 September 2017
31/10/17PRICE SENSITIVE download Created with Sketch. 186.66KB
CP1 CannPal enters Research Agreement with Queensland University
30/10/17PRICE SENSITIVE download Created with Sketch. 338.68KB
CP1 CP1 Ethics Approval
25/10/17PRICE SENSITIVE download Created with Sketch. 86.22KB
CP1 Admission to Official Quotation
23/10/17PRICE SENSITIVE download Created with Sketch. 90.48KB
refresh Created with Sketch. REFRESH
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
Add to My Watchlist

Top Stories

Amaero's big move: Exclusive deal, big targets, and a lot on the line

Amaero has just pulled off a deal that establishes its first-mover advantage: An exclusive five-year supply agreement with Titomic.
Future Battery Minerals identifies strong regolith gold anomalism at Canyon Future Battery MD and CEO, Nick Rathjen, joins HotCopper to unpack the company's glittering assay results at its Miriam project.
Tuesday's HotCopper trends: Race Oncology, Paladin Energy, and other daily winners | Sep 16 Race Oncology has been trending on the HotCopper forums after the biotech firm submitted an intellectual property patent application.
Market Close: Asian markets are visibly cautious, and gold profit-taking underscores that Good Afternoon and Welcome to HotCopper’s Market Close for Tuesday 16 September, I’m Jon Davidson. The index came back to life on Tuesday after Wall Street notched fresh records overnight, US futures just in the green once more in the final hour of trade. The next ...
Listen: HotCopper Wire Podcast 024 – Two '4D' stocks to watch, but only one winner In this HotCopper Wire Week 37 episode, we take a look at the Coles and Woolies legal fight and compare 4DMedical and 4DS Memory.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.